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Novel imaging techniques with ever-increasing resolution are
invaluable tools for the study of protein deposition, as they allow
the self-assembly of proteins to be directly investigated in living
cells. For the first time, the acceleration in A42 aggregation
inducedby theArcticmutationwasmonitored in cells, revealing
a number of distinct morphologies that form sequentially. This
approach will help discriminate the impacts of mutations on
amyloid protein processing, A aggregation propensity, and
other mechanistic outcomes.
Approximately 50 million people worldwide live with some
form of dementia; according to the Alzheimer’s Association,
two-thirds of this number suffer from Alzheimer’s disease, a
progressive neurodegenerative disorder affecting the associa-
tion cortices and hippocampus of the brain and leading to an
inexorable decline of cognitive abilities and memory. Genetic
evidence and time courses of a variety of brain-imaging modal-
ities and fluid-based biomarkers available today show that the
abnormal formation, aggregation, and accumulation in the
form of extracellular amyloid plaques of a short peptide (A40
or A42)2 are early causative events of the disease, which has
been termed the amyloid cascade hypothesis (1). Considerable
knowledge has been obtained on the aggregation process of the
A peptide in vitro, including the detection of various forms of
oligomeric intermediates and fibrillar forms of the peptide, as
well as characterization of their morphology and structure,
kinetics of formation and conversion into other species, and
toxicity (2). However, limited information is available on the
aggregation process in vivo, mainly due to our technical limita-
tions in monitoring the various steps of the process and in the
elucidation of its mechanism.
Recently, key innovations in light microscopy have bypassed
the earlier limits of optical resolution andmade optical micros-
copy one of the most powerful and flexible diagnostic tools in
cell biology (3). New super-resolution technologies can moni-
tor tailored illumination, nonlinear fluorophore responses, or
the precise localization of single molecules and aggregates (4).
Overall, these cutting-edge approaches have created new pos-
sibilities to investigate the complex structure and function of
macromolecules in living cells. Using highly specific fluores-
cence labeling techniques such as immunocytochemistry, in
situ hybridization, or fluorescent protein tags, the spatial distri-
bution and dynamics of subcellular compartments, proteins, or
genomic sequences of interest are currently being analyzed in
chemically fixed or living samples to answer themost challeng-
ing experimental designs (4).
The paper by Lu et al. (5) provides a welcome demonstration
of these advances in their study of the aggregation propensity
and stability of the “Arctic” mutant (E22G or E693G) A42
aggregates in engineered human embryonic kidney cells. The
authors were able, in particular, to characterize the nature and
dynamics of the A42 peptide assemblies in living cells using
fluorescence-lifetime imaging microscopy (FLIM) to monitor
the conversion of soluble protein fragments into amyloid
fibrils. The structural heterogeneity of the protein aggregates
was also examinedusing 3D structural illuminationmicroscopy
(SIM), which reveals morphological and structural details of
aggregated protein species by reconstructions from a series of
2D SIM sectioning images. The high-resolution images
revealed distinct morphologies of intracellular protein aggre-
gates at different stages of maturation, reflecting the assembly
of the monomeric peptides into small oligomeric species, olig-
omers into fibrils, and further assembly of these species into
fibril bundles, larger clusters, and aggresomes. The authors
were additionally able to show that the aggregates were not
degraded as quickly as WT aggregates and that this was likely
due to more tightly bound fibrils rather than a consequence of
the protein degradation machinery being overwhelmed, in line
with the expected biophysical outcome of the E22G mutation.
Themain strength of this study was the live-imaging capability,
such that protein aggregates at high resolution in a physiologi-
cal environment could be observed. This paper paves the way
for future studies targeting the effect of additional mutations,
chaperones, and inhibitors of the aggregation process.
Another strength of the study is that, although the Arctic
E22G mutation has previously been shown to promote self-
assembly of A42 (6), here the authors dissect the whole pro-
cess of E22GA42 aggregation into its various steps in the cells,
revealing that both oligomer and fibril formationwere faster for
the mutant protein relative to the WT counterpart. This is an
important point, as it is generally assumed that mutations
involving the precursor protein of A are pathogenic because
they promote cleavage at either the -secretase or -secretase
sites, resulting in increased formation of A or of A42 relative
to A40. However, the Arctic mutation seems to be solidifying
a new class of mutations rather than serving as a lone exception
to the cleavage rule. A detailed survey of the literature indicates
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that a considerable number of the mutations do not have such
an effect on APP processing. In fact, in addition to the various
mutations causing a duplication of the APP protein (7), 27
mutations have been found to be associated with the gene cod-
ing for the APP protein and to cause early onset Alzheimer’s
disease or related disorders (http://www.molgen.ua.ac.be/
ADMutations/default.cfm?MT0&ML1&PageAD and
references therein).3 Of these, 14 mutations are downstream of
the cleavage sites of -secretases (Fig. 1) and increase the spec-
ificity of -secretase for the cleavage after residue 713, increas-
ing the concentration ratio of the A42 and A40 forms (8).
One double mutation (known as the Swedish mutation,
K670N/M671L), immediately before the N terminus, and two
mutations located inside the region of theAPP sequence coding
for A42, the A673V mutation and the Flemish A692G muta-
tion, render the APP protein a better substrate for -secretases
with consequent overproduction of both forms of A (9, 10).
The remaining 10 mutations involving the A42 sequence,
including the E693Q, E693G, E693K, Glu693, D694N, and
A713T mutations, were not found to increase the specificity of
any secretase, resulting in unchanged or even decreased levels
of A (2). All of the 10 mutations are expected on theoretical
grounds to increase A aggregation rate, and for a few of them
this hypothesis was also experimentally confirmed (2).
These considerations further enhance the importance of the
study by Lu et al. (5) and urge a more systematic study of all the
various APP mutations on A aggregation in vivo. The techni-
cal advancements that allow the investigators to quantify the
rate of formation of the various forms of deposits are undoubt-
edly of great value in this research field. It would also be valua-
ble to test these new methods on primary neurons and extend
the analysis to the formation of the initial oligomeric species in
its different steps.
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Figure 1. Sequence and mutations of APP. The extracellular N-terminal domain (residues 18–671), the A42 sequence (residues 672–713), and the intra-
cellular C-terminal domain (residues 714–770) are shown in green, orange, and gray, respectively. The transmembrane domain encompasses residues 700–
723.Mutations that have been shown to induce an enhancement of the A aggregation propensity are reported above.Mutations that alter the processing of
the APP sequence are reported below. The Arctic mutation (E22G or E693G) is labeled in red.
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